KenyaTuberculosis profile
Population  2014 45 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 9.4 (6.7–12) 21 (15–28)
Mortality (HIV+TB only) 8.1 (6.4–10) 18 (14–22)
Prevalence  (includes HIV+TB) 120 (64–190) 266 (142–427)
Incidence  (includes HIV+TB) 110 (110–110) 246 (240–252)
Incidence (HIV+TB only) 40 (38–42) 89 (84–93)
         
Case detection, all forms (%) 80 (78–82)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.2 (0.3–4.1) 14 (12–15)
MDR-TB cases among notified pulmonary
TB cases
1 400 (200–2 700) 1 100 (930–1 200)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 34 997   3 569
Pulmonary, clinically diagnosed 30 872   2 947
Extrapulmonary 14 640   1 000
       
Total new and relapse 88 025    
Previously treated, excluding relapses 1 269    
Total cases notified 89 294    
Among 89 294 new and relapse cases:
8 448 (9%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 17 619 (50%) 7 436 (85%) 23 865
Laboratory-confirmed RR-/MDR-TB cases     644
Patients started on MDR-TB treatment ***     544
TB/HIV 2014 Number (%)
TB patients with known HIV status 84 423 (95)
HIV-positive TB patients 30 002 (36)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 29 735 (99)
HIV-positive TB patients on antiretroviral therapy (ART) 26 142 (87)
HIV-positive people screened for TB 426 102  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (86) 81 255
Previously treated cases registered in 2013 (78) 8 445
HIV-positive TB cases, all types, registered in 2013 (79) 31 755
RR-/MDR-TB cases started on second-line treatment in 2012 (83) 197
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 4.3
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 70
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 45
% Funded domestically 26%
% Funded internationally 28%
% Unfunded 45%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-25 Data: www.who.int/tb/data